| Determination of genetic predisposition to patent ductus arteriosus in preterm infants. | |
| | |
MedLine Citation:
|
PMID: 19336370 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Patent ductus arteriosus is a common morbidity associated with preterm birth. The incidence of patent ductus arteriosus increases with decreasing gestational age to approximately 70% in infants born at 25 weeks' gestation. Our major goal was to determine if genetic risk factors play a role in patent ductus arteriosus seen in preterm infants. METHODOLOGY: We investigated whether single-nucleotide polymorphisms in genes that regulate smooth muscle contraction, xenobiotic detoxification, inflammation, and other processes are markers for persistent patency of ductus arteriosus. Initially, 377 single-nucleotide polymorphisms from 130 genes of interest were evaluated in DNA samples collected from 204 infants with a gestational age of <32 weeks. A family-based association test was performed on genotyping data to evaluate overtransmission of alleles. RESULTS: P values of <.01 were detected for genetic variations found in 7 genes. This prompted additional analysis with an additional set of 162 infants, focusing on the 7 markers with initial P values of <.01, and 1 genetic variant in the angiotensin II type I receptor previously shown to be related to patent ductus arteriosus. Of the initial positive signals, single-nucleotide polymorphisms in the transcription factor AP-2 beta and tumor necrosis factor receptor-associated factor 1 genes remained significant. Additional haplotype analysis revealed genetic variations in prostacyclin synthase to be associated with patent ductus arteriosus. An angiotensin II type I receptor polymorphism previously reported to be associated with patent ductus arteriosus after prophylactic indomethacin administration was not associated with the presence of a patent ductus arteriosus in our population. CONCLUSIONS: Overall, our data support a role for genetic variations in transcription factor AP-2 beta, tumor necrosis factor receptor-associated factor 1, and prostacyclin synthase in the persistent patency of the ductus arteriosus seen in preterm infants. |
| | |
Authors:
|
John M Dagle; Nathan T Lepp; Margaret E Cooper; Kendra L Schaa; Keegan J P Kelsey; Kristin L Orr; Diana Caprau; Cara R Zimmerman; Katherine M Steffen; Karen J Johnson; Mary L Marazita; Jeffrey C Murray |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pediatrics Volume: 123 ISSN: 1098-4275 ISO Abbreviation: Pediatrics Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-01 Completed Date: 2009-04-28 Revised Date: 2013-05-13 |
Medline Journal Info:
|
Nlm Unique ID: 0376422 Medline TA: Pediatrics Country: United States |
Other Details:
|
Languages: eng Pagination: 1116-23 Citation Subset: AIM; IM |
Affiliation:
|
Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA. john-dagle@uiowa.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cholesterol Ester Transfer Proteins
/
genetics Cytochrome P-450 CYP2D6 / genetics Cytochrome P-450 Enzyme System / genetics Ductus Arteriosus, Patent / genetics* Genetic Predisposition to Disease / epidemiology* Gestational Age Haplotypes Humans Infant, Newborn Infant, Premature Infant, Premature, Diseases / genetics* Intramolecular Oxidoreductases / genetics Lipase / genetics Polymorphism, Single Nucleotide* Receptor, Angiotensin, Type 1 / genetics Receptors, Corticotropin-Releasing Hormone / genetics TNF Receptor-Associated Factor 1 / genetics Transcription Factor AP-2 / genetics |
| Grant Support | |
ID/Acronym/Agency:
|
M01 RR000059-466795/RR/NCRR NIH HHS; P30 ES005605-170010/ES/NIEHS NIH HHS; P30 ES005605-180010/ES/NIEHS NIH HHS; P30 ES05605/ES/NIEHS NIH HHS; R01 HD052953/HD/NICHD NIH HHS; R01 HD052953-01/HD/NICHD NIH HHS; R01 HD052953-01/HD/NICHD NIH HHS; T32 HD041922/HD/NICHD NIH HHS; T32 HD041922-02/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/CETP protein, human; 0/CRF receptor type 1; 0/Cholesterol Ester Transfer Proteins; 0/Receptor, Angiotensin, Type 1; 0/Receptors, Corticotropin-Releasing Hormone; 0/TFAP2B protein, human; 0/TNF Receptor-Associated Factor 1; 0/Transcription Factor AP-2; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.14.1/Cytochrome P-450 CYP2D6; EC 3.1.1.3/Lipase; EC 5.3.-/Intramolecular Oxidoreductases; EC 5.3.99.4/prostacyclin synthetase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A prospective study of ventilator-associated pneumonia in children.
Next Document: Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants.